Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 6/20 | 1.00 |
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 0.84 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.73 |
| ▸ | HPGD | P15428 | 8/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | MAOA | P21397 | 2/20 | 0.73 |
| ▸ | MAOB | P27338 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calycosin SCHEMBL30335127 | 0.91 | KDM4E (1.00) | KDM4EHSD17B10MAPTNPC1RAB9A | |
| SCHEMBL2069826 | 0.91 | KDM4E (0.84) | KDM4EHSD17B10MAPTNPC1RAB9A | |
| Calycosin SCHEMBL73013 | 0.91 | KDM4E (1.00) | KDM4EHSD17B10MAPTNPC1RAB9A | |
| SCHEMBL29788255 | 0.91 | KDM4E (0.84) | KDM4EHSD17B10MAPTNPC1RAB9A | |
| SCHEMBL30238115 | 0.91 | KDM4E (0.83) | KDM4EHSD17B10MAPTNPC1RAB9A | |
| SCHEMBL28124530 | 0.89 | KDM4E (0.80) | KDM4EHSD17B10MAPTNPC1RAB9A | |
| SCHEMBL13904731 | 0.87 | KDM4E (0.77) | KDM4EHSD17B10MAPTNPC1RAB9A | |
| SCHEMBL12206681 | 0.87 | KDM4E (0.77) | KDM4EHSD17B10MAPTNPC1RAB9A | |
| SCHEMBL10560560 | 0.86 | PTPN1 (0.77) | KDM4EHSD17B10MAPTNPC1RAB9A | |
| SCHEMBL13631294 | 0.86 | MAPT (0.77) | KDM4EHSD17B10MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9408826-B2 | Isoflavone anti-viral compounds | Kineta, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9408826-B2 | Isoflavone anti-viral compounds | Kineta, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9408826-B2 | Isoflavone anti-viral compounds | Kineta, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| EP-2560652-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8138184-B2 | Isoxazole derivatives and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2012-03-20 | — | — | US | disclosed |
| US-20110262482-A1 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262482-A1 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262482-A1 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2011133728-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133728-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-7247734-B2 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-07-24 | — | — | US | disclosed |
| WO-2006099681-A1 | ISOFLAVONOID DIMERS | NOVOGEN RESEARCH PTY LTD (AU) | 2006-09-28 | — | — | WO | disclosed |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| EP-1456180-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | Vernalis (Oxford) Ltd (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003055860-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2003-07-10 | — | — | WO | disclosed |
| EP-0710234-A1 | ISOFLAVONE DERIVATIVES | CHINOIN LTD. (HU) | 1996-05-08 | — | — | EP | disclosed |
| WO-1995003293-A1 | ISOFLAVONE DERIVATIVES | CHINOIN LTD. (HU) | 1995-02-02 | — | — | WO | disclosed |
| EP-0478558-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTITUTED ISOFLAVONE DERIVATIVES | CHINOIN GYOGYSZER ES VEGYESZET (HU) | 1994-02-02 | — | — | EP | disclosed |
| US-5247102-A | Cyclization of a resorcinol derivative with ethyl orthoformate in the presence of a base | CHINOIN GYOGYSZER- ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1993-09-21 | — | — | US | disclosed |
| WO-1991015483-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTITUTED ISOFLAVONE DERIVATIVES | CHINOIN GYÓGYSZER ÉS VEGYÉSZETI TERMÉKEK GYÁRA RT (HU) | 1991-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262482-A1 | ANTI-VIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | KDM4E 2601/4885HSD17B10 4165/4885MAPT 3520/4885 |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | HSP90AB1, HSP90AA1, HSP90AB2P | KDM4E 1999/4885HSD17B10 222/4885MAPT 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.